While the opinions and information expressed on this website have been obtained and derived from sources believed to be reliable, Ockham makes no representation, guarantee, or warranty as to the website’s accuracy, adequacy, timeliness or completeness. Prior years’ valuations, profitability, and growth parameters are not necessarily predictive of future share price ranges and past performance is no indication of future results. Because all investors have unique situations, objectives, and needs, statements on this website should not be taken as individual investment advice. I ssued for and on behalf of Ockham Biotech.This website and all reports or information displayed herein are provided for informational purposes only by Ockham Research, LLC (“Ockham”) and is not a recommendation or a solicitation to buy, sell, or hold a security. The COPD market is growing significantly in most countries and it is expected that COPD will be the fourth leading cause of death worldwide by 2030. In 2009, the COPD market was estimated to be worth $7.2 billion and is projected to grow at a compound annual growth rate (CAGR) of 7.4% to reach $11.9 billion in 2016.
About COPDĬOPD is predominantly caused by cigarette smoking and inhalation of environmental factors, including wood smoke from cooking over open fires, and is believed to affect up to 10% of the world population. is a research and development company specialising in the development of inhaled heparin for the treatment of obstructive airway diseases, including chronic obstructive pulmonary disease (COPD). Securing this patent was an important step for our company and we look forward to exciting opportunities to work with potential partners”.
#Ockham research company trial
Her invention provides a way to treat airway mucus obstruction in COPD and Ockham’s commissioned and on-going trial of inhaled heparin in patients with COPD support the safety and efficacy of this approach.
It will be a significant development in the therapeutic strategy for the millions of patients with COPD who suffer with symptoms of breathlessness, cough and difficulty expectorating mucus.”Īndy Short, CEO of Ockham Biotech, added, “The science behind Dr Shute’s discovery of the mucolytic effects of heparin is compelling. Mario Cazzola, Professor of Medicine at the University of Rome Tor Vergata, said: “An effective mucolytic for the relief of symptoms in COPD patients with mucus hypersecretion is urgently needed. The development of novel inhaled therapies, based on the multiple pharmacological properties of heparin, either alone or in combination with other drugs, is anticipated to provide new COPD treatment options, expanding the COPD market in the coming years. There is a high level of unmet need for drugs to reduce COPD exacerbation rates, slow or halt the progression of COPD, and improve lung function and the quality of life in COPD patients. In March 2013, the Technical Board of Appeal set aside the first instance decision of the Opposition Division and maintained Ockham’s European patent with claims directed to administration via inhalation, intranasally or instillation. The patent was subsequently opposed by Vectura plc and was revoked at first instance by the Opposition Division of the European Patent Office in 2011. The first European patent on the use of inhaled heparin as a mono-therapy was granted to Ockham in 2008. In addition to its multiple pharmacological and well-described anti-inflammatory properties, the use of inhaled heparin suggests an effective way to treat mucus hypersecretory diseases with airway mucus congestion. These properties provide a means to improve airway mucus clearance and a ‘ballistic effect’ to deliver other inhaled drugs to mucus-congested airways more effectively. In 2002, Ockham filed three patent applications based on the mucolytic properties of inhaled heparin that were discovered by Dr Janis Shute, Scientific Director for the Company. Swanwick, UK – 3 June 2013 – Ockham Biotech Ltd (‘Ockham’), a company specialising in the research, development and commercialisation of new therapies for respiratory disorders, is pleased to announce that its European patent covering the use of inhaled heparin for the treatment of patients with chronic obstructive pulmonary disease (COPD) and mucus hypersecretion has been restored, following its grant in 2008 and subsequent revocation in 2011. Ockham Biotech Overturns Vectura's Challenge to Secure European Patent Rights for Inhaled Heparin in the Treatment of COPD
0 kommentar(er)
